Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study

Daisuke Murakami, Motohiro Sawatsubashi, Sayaka Kikkawa, Masayoshi Ejima, Akira Saito, Akio Kato, Shizuo Komune

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: We have recently reported that a new regimen of short-term oral immunotherapy (OIT) with the Cry j1-galactomannan conjugate for Japanese cedar pollinosis (JCP) is effective to the improvement in the symptoms and medication use during the pollen season and relatively safe. The effect of OIT on quality of life (QOL) of JCP patients has not been assessed. Therefore, we evaluated for the first time the effect of OIT on QOL during the Japanese cedar/cypress pollen season. Methods: A prospective, randomized, open-label trial was conducted over a period of 4 months. Participants were randomly divided into two groups. The OIT and control groups comprised 23 and 24 subjects, respectively. The build-up phase was initiated 1 month before the expected pollen season. The maintenance phase was continued for 51 days during the peak of the cedar pollen season. The QOL score in the Japan Rhinoconjunctivitis Quality of Life Questionnaire (JRQLQ) No. 1 and visual analog scale (VAS) throughout the pollen season were evaluated. Results: Participants receiving OIT showed significant improvements in the total QOL score and VAS throughout the pollen season compared with the control group. In addition, the mean total QOL score and VAS correlated in both groups during the pollen season. Conclusion: The new regimen of short-term OIT using the Cry j1-galactomannan conjugate results in meaningful improvements in QOL of JCP patients. Our findings suggest that short-term OIT using allergen-galactomannan conjugates, as well as sublingual and subcutaneous immunotherapy, improves QOL of patients with pollinosis.The study was registered in UMIN-CTR (UMIN000013408) as the name of "a prospective, randomized, open study of oral Cry j1-galactomannan conjugate immunotherapy for Japanese cedar pollen allergy".

Original languageEnglish
Pages (from-to)50-55
Number of pages6
JournalAuris Nasus Larynx
Volume43
Issue number1
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Cryptomeria
Seasonal Allergic Rhinitis
Immunotherapy
Pollen
Quality of Life
Visual Analog Scale
Cupressus
Sublingual Immunotherapy
Immunologic Desensitization
Control Groups
galactomannan
Names
Japan
Maintenance

All Science Journal Classification (ASJC) codes

  • Surgery
  • Otorhinolaryngology

Cite this

Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients : A prospective, randomized, open-label study. / Murakami, Daisuke; Sawatsubashi, Motohiro; Kikkawa, Sayaka; Ejima, Masayoshi; Saito, Akira; Kato, Akio; Komune, Shizuo.

In: Auris Nasus Larynx, Vol. 43, No. 1, 01.02.2016, p. 50-55.

Research output: Contribution to journalArticle

Murakami, Daisuke ; Sawatsubashi, Motohiro ; Kikkawa, Sayaka ; Ejima, Masayoshi ; Saito, Akira ; Kato, Akio ; Komune, Shizuo. / Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients : A prospective, randomized, open-label study. In: Auris Nasus Larynx. 2016 ; Vol. 43, No. 1. pp. 50-55.
@article{55ed567d241e41a4b7800468b1644e75,
title = "Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients: A prospective, randomized, open-label study",
abstract = "Objective: We have recently reported that a new regimen of short-term oral immunotherapy (OIT) with the Cry j1-galactomannan conjugate for Japanese cedar pollinosis (JCP) is effective to the improvement in the symptoms and medication use during the pollen season and relatively safe. The effect of OIT on quality of life (QOL) of JCP patients has not been assessed. Therefore, we evaluated for the first time the effect of OIT on QOL during the Japanese cedar/cypress pollen season. Methods: A prospective, randomized, open-label trial was conducted over a period of 4 months. Participants were randomly divided into two groups. The OIT and control groups comprised 23 and 24 subjects, respectively. The build-up phase was initiated 1 month before the expected pollen season. The maintenance phase was continued for 51 days during the peak of the cedar pollen season. The QOL score in the Japan Rhinoconjunctivitis Quality of Life Questionnaire (JRQLQ) No. 1 and visual analog scale (VAS) throughout the pollen season were evaluated. Results: Participants receiving OIT showed significant improvements in the total QOL score and VAS throughout the pollen season compared with the control group. In addition, the mean total QOL score and VAS correlated in both groups during the pollen season. Conclusion: The new regimen of short-term OIT using the Cry j1-galactomannan conjugate results in meaningful improvements in QOL of JCP patients. Our findings suggest that short-term OIT using allergen-galactomannan conjugates, as well as sublingual and subcutaneous immunotherapy, improves QOL of patients with pollinosis.The study was registered in UMIN-CTR (UMIN000013408) as the name of {"}a prospective, randomized, open study of oral Cry j1-galactomannan conjugate immunotherapy for Japanese cedar pollen allergy{"}.",
author = "Daisuke Murakami and Motohiro Sawatsubashi and Sayaka Kikkawa and Masayoshi Ejima and Akira Saito and Akio Kato and Shizuo Komune",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.anl.2015.06.011",
language = "English",
volume = "43",
pages = "50--55",
journal = "Auris Nasus Larynx",
issn = "0385-8146",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of short-term oral immunotherapy with Cry j1-galactomannan conjugate on quality of life in Japanese cedar pollinosis patients

T2 - A prospective, randomized, open-label study

AU - Murakami, Daisuke

AU - Sawatsubashi, Motohiro

AU - Kikkawa, Sayaka

AU - Ejima, Masayoshi

AU - Saito, Akira

AU - Kato, Akio

AU - Komune, Shizuo

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective: We have recently reported that a new regimen of short-term oral immunotherapy (OIT) with the Cry j1-galactomannan conjugate for Japanese cedar pollinosis (JCP) is effective to the improvement in the symptoms and medication use during the pollen season and relatively safe. The effect of OIT on quality of life (QOL) of JCP patients has not been assessed. Therefore, we evaluated for the first time the effect of OIT on QOL during the Japanese cedar/cypress pollen season. Methods: A prospective, randomized, open-label trial was conducted over a period of 4 months. Participants were randomly divided into two groups. The OIT and control groups comprised 23 and 24 subjects, respectively. The build-up phase was initiated 1 month before the expected pollen season. The maintenance phase was continued for 51 days during the peak of the cedar pollen season. The QOL score in the Japan Rhinoconjunctivitis Quality of Life Questionnaire (JRQLQ) No. 1 and visual analog scale (VAS) throughout the pollen season were evaluated. Results: Participants receiving OIT showed significant improvements in the total QOL score and VAS throughout the pollen season compared with the control group. In addition, the mean total QOL score and VAS correlated in both groups during the pollen season. Conclusion: The new regimen of short-term OIT using the Cry j1-galactomannan conjugate results in meaningful improvements in QOL of JCP patients. Our findings suggest that short-term OIT using allergen-galactomannan conjugates, as well as sublingual and subcutaneous immunotherapy, improves QOL of patients with pollinosis.The study was registered in UMIN-CTR (UMIN000013408) as the name of "a prospective, randomized, open study of oral Cry j1-galactomannan conjugate immunotherapy for Japanese cedar pollen allergy".

AB - Objective: We have recently reported that a new regimen of short-term oral immunotherapy (OIT) with the Cry j1-galactomannan conjugate for Japanese cedar pollinosis (JCP) is effective to the improvement in the symptoms and medication use during the pollen season and relatively safe. The effect of OIT on quality of life (QOL) of JCP patients has not been assessed. Therefore, we evaluated for the first time the effect of OIT on QOL during the Japanese cedar/cypress pollen season. Methods: A prospective, randomized, open-label trial was conducted over a period of 4 months. Participants were randomly divided into two groups. The OIT and control groups comprised 23 and 24 subjects, respectively. The build-up phase was initiated 1 month before the expected pollen season. The maintenance phase was continued for 51 days during the peak of the cedar pollen season. The QOL score in the Japan Rhinoconjunctivitis Quality of Life Questionnaire (JRQLQ) No. 1 and visual analog scale (VAS) throughout the pollen season were evaluated. Results: Participants receiving OIT showed significant improvements in the total QOL score and VAS throughout the pollen season compared with the control group. In addition, the mean total QOL score and VAS correlated in both groups during the pollen season. Conclusion: The new regimen of short-term OIT using the Cry j1-galactomannan conjugate results in meaningful improvements in QOL of JCP patients. Our findings suggest that short-term OIT using allergen-galactomannan conjugates, as well as sublingual and subcutaneous immunotherapy, improves QOL of patients with pollinosis.The study was registered in UMIN-CTR (UMIN000013408) as the name of "a prospective, randomized, open study of oral Cry j1-galactomannan conjugate immunotherapy for Japanese cedar pollen allergy".

UR - http://www.scopus.com/inward/record.url?scp=84958053288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958053288&partnerID=8YFLogxK

U2 - 10.1016/j.anl.2015.06.011

DO - 10.1016/j.anl.2015.06.011

M3 - Article

C2 - 26197940

AN - SCOPUS:84958053288

VL - 43

SP - 50

EP - 55

JO - Auris Nasus Larynx

JF - Auris Nasus Larynx

SN - 0385-8146

IS - 1

ER -